Džubák Petr M.D., Ph.D.
E-mail:
petr.dzubak@upol.cz
Phone:
+420 585632150, +420 604851158
Groups:
IMTM, LEM, STAFF, SUPERVISOR
About me
Scientist and pediatrician involved in molecular and translational medicine (disease area oncology and infectious diseases), leader of research program Chemical Biology and Experimental Therapeutics at IMTM. Actively participated in the research of more than 20 national and international projects; member of advisory board of Cancer Research Foundation „Rakovina ve veřejná“, co-founder of spin-off company focused on manufacturing of molecular diagnostics. Published more than >140 papers and books/chapters, >3552 SCI citations, H-index 27, Prix de Pharmacie 2007 Ambassade de France – Sanofi-aventis, Premier Prix.
Specialties: Molecular and translational medicine, Oncology, Drug research and development, MOA, Drug resistance
Journals
2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines.
International Journal of Molecular Medicine.
2022,
49(3),
31,
ISSN: 1107-3756,
PMID: 35039871,
An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry.
Biomedicine & Pharmacotherapy.
2022,
146,
112549,
ISSN: 0753-3322,
PMID: 34923338,
Intellectual property
METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS AND OVERCOMIMG THEIR RESISTANCE (Madhu)
- Published Application PCT/CZ2012/000123 under WO 2013/083098 (13.6.2013)
- Patent: EP 2788504; Granted: 21.7.2016; Ownership: Palacky University Olomouc, Institute of Animal Physiology and Genetics CAS; Inventors: Kollaredy Madhusudhan, Hajdúch Marián, Džubák Petr, Srovnal Josef, Hrabáková, Kovářová Hana
- Patent: JP 6144696; Granted: 19.5.2017; Ownership: Palacky University Olomouc, Institute of Animal Physiology and Genetics CAS; Inventors: Kollaredy Madhusudhan, Hajdúch Marián, Džubák Petr, Srovnal Josef, Hrabáková, Kovářová Hana
- Patent: CA 2.855.921; Granted: 5.3.2019; Ownership: Palacky University Olomouc, Institute of Animal Physiology and Genetics CAS; Inventors: Kollaredy Madhusudhan, Hajdúch Marián, Džubák Petr, Srovnal Josef, Hrabáková, Kovářová Hana
- Published Application US 2014/0336073 (13.11.2014)
Status: Terminated
SUBSTITUTED 7-DEZAPURIN RIBONUCLEOSIDES (Hocek)
- Patent: JP 5485172; Granted: 7.5.2014; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Palacky University Olomouc; Inventors: Hocek Michal, Nauš Petr, Caletková Olga, Džubák Petr, Hajdúch Marián
- Patent: CZ 305466; Granted: 7.9.2015; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Palacky University Olomouc; Inventors: Hocek Michal, Nauš Petr, Caletková Olga, Džubák Petr, Hajdúch Marián
- Patent: AU 20142777740; Granted: 25.2.2016; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Palacky University Olomouc; Inventors: Hocek Michal, Nauš Petr, Caletková Olga, Džubák Petr, Hajdúch Marián
- Patent: US 9,586,986; Granted: 7.3.2017; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Palacky University Olomouc; Inventors: Hocek Michal, Nauš Petr, Caletková Olga, Džubák Petr, Hajdúch Marián
Status: Available
CAFFEINE-8-HYDRAZONES AS NOVEL CYTOSTATICS FOR THE TREATMENT OF ONCOLOGIC DISEASES (Kaplánek)
- Patent: CZ 305625; Granted: 2.12.2015; Ownership: Institute of Chemical Technology Prague, Palacky University Olomouc, Institute of Molecular Genetics CAS; Inventors: Rak Jakub, Kaplánek Robert, Štulcová Tereza, Drašar Pavel, Havlík Martin, Bříza Tomáš, Džubák Petr, Hajdúch Marián, Konečný Petr, Štěpánková Jana, Králová Jarmila, Král Vladimír
Status: Terminated
Open positions
| Project: | Identification of proteomic biomarkers in exhaled air condensate in patients with systemic or pulmonary disease |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Antitumor drugs targeting nucleic acid metabolism |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Identification of molecular targets and mechanisms of resistance in antitumor drugs using cell biology and proteomics methods |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | 2 places in full-time study |
| Project: | Genetic and epigenetic biomarkers of cancer diseases |
|---|---|
| Supervisors: | Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 3 |
| Intended for: | Doctoral training |
| Summary: | 3 places in full-time study |
| Project: | Identification of proteomic biomarkers in exhaled breath condensate in patients with systemic or pulmonary disease |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | Ph.D. topic is focused on the identification of biomarkers of lung diseases by means of a non-invasive collection of exhaled breath condensate. The project will monitor the presence of proteins in exhaled air in various diseases such as asthma, cystic fibrosis, lung tumors, or some infectious diseases, as well as quantitative changes of these proteins compared to a healthy population. Changes in these potential biomarkers with respect to therapeutic response and disease progression will be evaluated and validated. |
| Project: | Identification of molecular targets of anticancer therapy applying cell biology and proteomics tools |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | Selected, highly active derivatives of triterpenes, chelators and nucleosides will be studied with a view to identify the mechanisms of their antitumor effects. Advanced methods of cell biology, proteomics and genomics such as affinity purification of protein targets, CETSA and others will be used for their study. The identified targets will be validated in relation to their clinical relevance in anticancer therapy. |
| Project: | Drug resistance mechanisms in cancer |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Summary: | Mechanisms of tumor cell resistance to newly developed and existing nucleoside analog cytostatics will be studied. These drugs are used in most anti-cancer therapy protocols and the emergence of drug resistance is a major problem in the treatment of cancer patients. Resistant cell lines prepared in the past will be studied to identify the key mechanisms of resistance, which will be carried out by their detailed characterization using cell biology, but also proteomics and molecular genetics. The significance of the identified changes will be further verified on clinical material and will be applied in the development of new anticancer drugs from this class. |
| Project: | Research and development of agents for cancer, neurodegenerative and infectious diseases |
|---|---|
| Supervisors: | De Sanctis Juan Bautista Ph.D., Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D., Urban Milan Ph.D., Das Viswanath M.Sc., Ph.D. |
| Available: | 5 |
| Intended for: | Doctoral training |
| Project: | Genetic and epigenetic biomarkers in health and disease |
|---|---|
| Supervisors: | Slavkovský Rastislav Ph.D., Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D., Drábek Jiří Ph.D., Koudeláková Vladimíra Ph.D. |
| Available: | 5 |
| Intended for: | Doctoral training |
| Project: | Identification of molecular targets and resistance mechanisms of anticancer drugs by cell biology and proteomics methods |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Identification of proteomic biomarkers in exhaled breath condensate patients with systemic or pulmonary disease |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Identification of proteomic biomarkers in proximal fluids and tissues |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Hajdúch Marián M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |
| Project: | Innovative approaches to protein interaction modifiers |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D., Václavková Jana M.Sc. |
| Available: | 1 |
| Intended for: | Doctoral training |
| Project: | Utilization of the space of unprecedented covalent inhibitors |
|---|---|
| Supervisors: | Džubák Petr M.D., Ph.D. |
| Available: | 1 |
| Intended for: | Doctoral training |
| Project: | Anticancer drugs targeting nucleic acid metabolism |
|---|---|
| Supervisors: | Hajdúch Marián M.D., Ph.D., Džubák Petr M.D., Ph.D. |
| Available: | 2 |
| Intended for: | Doctoral training |